Effects of Sand Treatment on Osteoarthritis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03943303 |
|
Recruitment Status :
Terminated
(Because the Pandemia COVID-19 was not possible to bring the participants to the beach.)
First Posted : May 9, 2019
Last Update Posted : October 28, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Osteo Arthritis Knee | Radiation: Natural gamma radiation from the monazite sands Radiation: Normal sands exposure patients | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 150 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | The study will be carried out on the beaches of Areia Preta de Guarapari (source of monazitic sands) and on the beach of Itapoã in Vila Velha (sand without radiation). Selected patients will have their knees fully covered with beach sand, properly analyzed for radioactivity and temperature, for 30 minutes on 2 mornings a week for a period of 1 (one) year. |
| Masking: | Single (Outcomes Assessor) |
| Masking Description: | The outcomes assessor is unaware of the treatment that the patients received. |
| Primary Purpose: | Health Services Research |
| Official Title: | Effect of Monazite Sands in Patients With Osteoarthritis of the Knee |
| Actual Study Start Date : | July 28, 2021 |
| Actual Primary Completion Date : | July 28, 2021 |
| Actual Study Completion Date : | August 23, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Natural gamma radiation from the monazite sands
Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day. The natural gamma radiation doses of the monazite sands will be monitored, the radiation measurements gamma will be associated with the atmospheric and climatic measurements of each group. It is understood here as atmospheric measurements, level of solar radiation, spectrum of sunlight at the time of exposure, humidity, wind speed, ultraviolet radiation level, amount of ions present in the air and measurements of the magnetic field in the place.
|
Radiation: Natural gamma radiation from the monazite sands
Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
Other Name: Natural beach black sands |
|
Placebo Comparator: Normal sands exposure patients
Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day. To ensure the absence of radiation, mesuaraments of possible radiation will be monitored.
|
Radiation: Normal sands exposure patients
Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
Other Name: No-monazite sands |
- Change in the Visual analgesic scale (0-10) [ Time Frame: 1, 3, 6, 8 and 12 months ]Change pain perception through the visual analgesic scale of the volunteers. It consists of a graduated scale of 0 to 10 with regular intervals where zero means absence of pain and 10 is the maximum pain already experienced by the patient.
- Change total score (0 - 96) the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)- (lower scores indicate lower levels of symptoms or physical disability) [ Time Frame: 1, 3, 6, 8 and 12 months ]Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire comprises three subscale. The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function.
- Change the number of patient with higher concentration of Nonspecific inflammatory markers [ Time Frame: 1, 3, 6, 8 and 12 months ]Quantification of nonspecific inflammatory markers (HSV and CRP) and specific (IL-1β, IL-6, IL-8, IL-17, TNF-α and TGF-β) per patient
- Change the frequency of Self-medicatition to treat pain [ Time Frame: 1, 3, 6, 8 and 12 months ]Evaluation of the frequency of self-medication before and during the intervention
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 30 Years to 95 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Joint pain related to daily activities;
- No morning joint stiffness greater than 30 minutes;
- Age between 30 and 95 years.
Exclusion Criteria:
- History of previous knee surgery.
- History of fracture in the knee region.
- History of any secondary OA associated with any cystic arthropathy.
- Any treatment for the knee with methotrexate.
- History of hemorrhagic disorders.
- History of any infiltration of the knee during the previous 6 months (eg corticosteroids and hyaluronic acid).
- Morbid obesity.
- History of severe psychiatric disorders.
- History of skin cancer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03943303
| Brazil | |
| Denise Coutinho Endringer | |
| Vila Velha, ES, Brazil, 29103790 | |
| Principal Investigator: | DENISE C Endringer, Dr | UVila Velha |
Documents provided by Denise Coutinho Endringer, University Vila Velha:
Publications of Results:
| Responsible Party: | Denise Coutinho Endringer, Director of Research and graduate program, University Vila Velha |
| ClinicalTrials.gov Identifier: | NCT03943303 |
| Other Study ID Numbers: |
T015-M02-2019AF002 TO#617/2018 ( Other Grant/Funding Number: FUNCITEC/MCI ) |
| First Posted: | May 9, 2019 Key Record Dates |
| Last Update Posted: | October 28, 2021 |
| Last Verified: | October 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
monazitc sands radiation |
|
Osteoarthritis Osteoarthritis, Knee Arthritis |
Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |

